Innospec Inc. (IOSP) Analysts See $0.98 EPS on May, 8

April 16, 2018 - By Roy Fason

Innospec Inc. (NASDAQ:IOSP) Corporate Logo

On May, 8 Innospec Inc. (NASDAQ:IOSP)’s earnings report is anticipated by WallStreet, Zacks reports. Analysts predict $0.98 EPS. That’s $0.02 down or 2.00 % from 2017’s earnings of $1. IOSP’s profit could hit $24.30 million if the current EPS of $0.98 is accurate. -33.33 % negative EPS growth is what Wall Street’s sees after $1.47 reported EPS last quarter. The stock increased 2.90% or $2.05 during the last trading session, reaching $72.75.Innospec Inc. has 157,557 shares volume, 39.76% up from normal. IOSP is uptrending and has moved 10.33% since April 17, 2017. IOSP underperformed the S&P500 by 1.22%.

Innospec Inc. (NASDAQ:IOSP) Ratings Coverage

In total 3 analysts cover Innospec (NASDAQ:IOSP). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 3 are the (NASDAQ:IOSP)’s analyst reports since November 9, 2017 according to StockzIntelligence Inc. In Thursday, November 9 report KeyBanc Capital Markets maintained the stock with “Overweight” rating. The company rating was upgraded by Johnson Rice on Tuesday, November 14. On Thursday, November 9 the company was downgraded by Monness Crespi & Hardt.

Innospec Inc. develops, manufactures, blends, markets, and supplies fuel additives, oilfield chemicals, personal care products, and other specialty chemicals to gas and oil exploration and production, oil refinery, fuel users, personal care formulation, home care, agrochemical and mining formulation, and other chemical and industrial companies worldwide.The firm is worth $1.80 billion. It operates through four divisions: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.28.87 is the P/E ratio. The Fuel Specialties segment offers a range of specialty chemical products used as additives in various fuels.

Innospec Inc. (NASDAQ:IOSP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.